Summit Therapeutics Inc.
SMMT | NASDAQ
$17.16
+$0.26 (+1.54%)
Sep 22, 2026, 11:49 AM ET · Market open
Market Data
Market Cap $13.48B
Enterprise Value $12.81B
Beta -1.24
Average Volume 5.38M
Shares Outstanding (Diluted) 778.18M
Shares Change YoY 4.79%
Institutional Ownership 15.34%
Exchange NASDAQ
ISIN US86627T1088
Price Performance
Price Change 1M 29.3%
Price Change 3M 18.6%
Price Change 6M -5.8%
Price Change YTD -3.5%
Price Change 1Y -11.5%
Price Change 3Y 803.7%
Price Change 5Y 223.8%
1M CAGR (ann.) 21.1%
1Y CAGR (ann.) -12.1%
5Y CAGR (ann.) 21.8%
All-Time CAGR 4.5%
Valuation
PE Ratio -15.09
Forward PE N/A
PEG Ratio 0.32
Forward PEG 6.37
PS Ratio N/A
Forward PS 226.50
PB Ratio 21.40
P/FCF Ratio -33.15
P/Adj. FCF Ratio -18.51
P/OCF Ratio -32.50
EV/Sales N/A
EV/EBIT -14.97
EV/EBITDA -14.97
EV/FCF -31.50
Earnings Yield -6.6%
FCF Yield -3.0%
Adj. FCF Yield -5.4%
Financial Health
Net Cash $670.29M
Total Debt $20.38M
Cash & Short-Term Investments $690.68M
Total Assets $752.19M
Current Ratio 6.96
Quick Ratio 6.96
Debt / Equity Ratio 0.03
Debt / EBITDA -0.02
Debt / FCF -0.05
OCF / Debt -19.89
Interest Coverage 0.00
Altman Z-Score 58.40
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -79.1%
Returns
Return on Assets -113.8%
Return on Equity -204.3%
Return on Invested Capital -134.1%
Return on Capital Employed -134.9%
Return on Tangible Assets -114.1%
Historical Growth (CAGR)
Revenue CAGR 3Y N/A
Revenue CAGR 5Y -94.3%
Revenue CAGR 10Y -41.3%
EPS CAGR 3Y -67.4%
EPS CAGR 5Y -3.5%
EPS CAGR 10Y -14.3%
FCF CAGR 3Y -76.7%
FCF CAGR 5Y -56.0%
FCF CAGR 10Y -35.6%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 23
EPS Growth Next 3Y 35.7%
Revenue Growth Next 3Y N/A
Earnings Date Oct 18, 2026
EPS Estimate (next Q) -$0.28
EPS Growth Est (next Q) -9.7%
Revenue Est (next Q) $71.43K
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $26.86
Price Target Upside 58.9%
Cash Flow
Operating Cash Flow $-405.37M
Free Cash Flow $-406.69M
Adj. Free Cash Flow $-728.35M
FCF Per Share -$0.52
OCF Per Share -$0.52
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $0
Operating Income $-874.79M
EBITDA $-855.91M
Net Income $-856.09M
EPS (Diluted) -$1.12
Revenue / Employee N/A
Profit / Employee $-3.23M
Employees 265
Add to Watchlist
Select watchlists to add or remove SMMT